The OVAREX study: Establishment of ex vivo ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers
Author(s) :
Thorel, L. [Auteur]
Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers [ANTICIPE]
Divoux, J. [Auteur]
Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers [ANTICIPE]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
Lequesne, J. [Auteur]
Babin, G. [Auteur]
Morice, P. M. [Auteur]
Florent, R. [Auteur]
Desmartin, G. [Auteur]
Lecouflet, L. [Auteur]
Marde Alagama, C. [Auteur]
Leconte, A. [Auteur]
Clarisse, B. [Auteur]
Briand, M. [Auteur]
Rouzier, R. [Auteur]
Gaichies, L. [Auteur]
Martin-Françoise, S. [Auteur]
Le Brun, J. F. [Auteur]
Denoyelle, C. [Auteur]
Vigneron, N. [Auteur]
Jeanne, C. [Auteur]
Blanc-Fournier, C. [Auteur]
Leman, R. [Auteur]
Vaur, D. [Auteur]
Figeac, Martin [Auteur]
Genomic @ Lille - PLBS [GO@L]
Meryet-Figuiere, M. [Auteur]
Joly, F. [Auteur]
Weiswald, L. B. [Auteur]
Poulain, L. [Auteur]
Dolivet, E. [Auteur]
Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers [ANTICIPE]
Divoux, J. [Auteur]
Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers [ANTICIPE]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
Lequesne, J. [Auteur]
Babin, G. [Auteur]
Morice, P. M. [Auteur]
Florent, R. [Auteur]
Desmartin, G. [Auteur]
Lecouflet, L. [Auteur]
Marde Alagama, C. [Auteur]
Leconte, A. [Auteur]
Clarisse, B. [Auteur]
Briand, M. [Auteur]
Rouzier, R. [Auteur]
Gaichies, L. [Auteur]
Martin-Françoise, S. [Auteur]
Le Brun, J. F. [Auteur]
Denoyelle, C. [Auteur]
Vigneron, N. [Auteur]
Jeanne, C. [Auteur]
Blanc-Fournier, C. [Auteur]
Leman, R. [Auteur]
Vaur, D. [Auteur]
Figeac, Martin [Auteur]

Genomic @ Lille - PLBS [GO@L]
Meryet-Figuiere, M. [Auteur]
Joly, F. [Auteur]
Weiswald, L. B. [Auteur]
Poulain, L. [Auteur]
Dolivet, E. [Auteur]
Journal title :
BMC Cancer
Volume number :
24
Pages :
701
Publication date :
2024-06-10
ISSN :
1471-2407
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Background
Ovarian cancer is the first cause of death from gynecological malignancies mainly due to development of chemoresistance. Despite the emergence of PARP inhibitors, which have revolutionized the therapeutic ...
Show more >Background Ovarian cancer is the first cause of death from gynecological malignancies mainly due to development of chemoresistance. Despite the emergence of PARP inhibitors, which have revolutionized the therapeutic management of some of these ovarian cancers, the 5-year overall survival rate remains around 45%. Therefore, it is crucial to develop new therapeutic strategies, to identify predictive biomarkers and to predict the response to treatments. In this context, functional assays based on patient-derived tumor models could constitute helpful and relevant tools for identifying efficient therapies or to guide clinical decision making. Method The OVAREX study is a single-center non-interventional study which aims at investigating the feasibility of establishing in vivo and ex vivo models and testing ex vivo models to predict clinical response of ovarian cancer patients. Patient-Derived Xenografts (PDX) will be established from tumor fragments engrafted subcutaneously into immunocompromised mice. Explants will be generated by slicing tumor tissues and Ascites-Derived Spheroids (ADS) will be isolated following filtration of ascites. Patient-derived tumor organoids (PDTO) will be established after dissociation of tumor tissues or ADS, cell embedding into extracellular matrix and culture in specific medium. Molecular and histological characterizations will be performed to compare tumor of origin and paired models. Response of ex vivo tumor-derived models to conventional chemotherapy and PARP inhibitors will be assessed and compared to results of companion diagnostic test and/or to the patient’s response to evaluate their predictive value. Discussion This clinical study aims at generating PDX and ex vivo models (PDTO, ADS, and explants) from tumors or ascites of ovarian cancer patients who will undergo surgical procedure or paracentesis. We aim at demonstrating the predictive value of ex vivo models for their potential use in routine clinical practice as part of precision medicine, as well as establishing a collection of relevant ovarian cancer models that will be useful for the evaluation of future innovative therapies.Show less >
Show more >Background Ovarian cancer is the first cause of death from gynecological malignancies mainly due to development of chemoresistance. Despite the emergence of PARP inhibitors, which have revolutionized the therapeutic management of some of these ovarian cancers, the 5-year overall survival rate remains around 45%. Therefore, it is crucial to develop new therapeutic strategies, to identify predictive biomarkers and to predict the response to treatments. In this context, functional assays based on patient-derived tumor models could constitute helpful and relevant tools for identifying efficient therapies or to guide clinical decision making. Method The OVAREX study is a single-center non-interventional study which aims at investigating the feasibility of establishing in vivo and ex vivo models and testing ex vivo models to predict clinical response of ovarian cancer patients. Patient-Derived Xenografts (PDX) will be established from tumor fragments engrafted subcutaneously into immunocompromised mice. Explants will be generated by slicing tumor tissues and Ascites-Derived Spheroids (ADS) will be isolated following filtration of ascites. Patient-derived tumor organoids (PDTO) will be established after dissociation of tumor tissues or ADS, cell embedding into extracellular matrix and culture in specific medium. Molecular and histological characterizations will be performed to compare tumor of origin and paired models. Response of ex vivo tumor-derived models to conventional chemotherapy and PARP inhibitors will be assessed and compared to results of companion diagnostic test and/or to the patient’s response to evaluate their predictive value. Discussion This clinical study aims at generating PDX and ex vivo models (PDTO, ADS, and explants) from tumors or ascites of ovarian cancer patients who will undergo surgical procedure or paracentesis. We aim at demonstrating the predictive value of ex vivo models for their potential use in routine clinical practice as part of precision medicine, as well as establishing a collection of relevant ovarian cancer models that will be useful for the evaluation of future innovative therapies.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
CNRS
Inserm
Institut Pasteur de Lille
CHU Lille
CNRS
Inserm
Institut Pasteur de Lille
Submission date :
2024-06-18T21:03:04Z
2024-08-29T09:07:39Z
2024-08-29T09:07:39Z
Files
- s12885-024-12429-w.pdf
- Version éditeur
- Open access
- Access the document